Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2008-07-01
2008-07-01
Mertz, Prema M (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S002600, C514S008100
Reexamination Certificate
active
07393523
ABSTRACT:
Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.
REFERENCES:
patent: 6093405 (2000-07-01), Zagury et al.
patent: 6440694 (2002-08-01), Bienkowski et al.
patent: 0 218 531 (1987-04-01), None
patent: WO 94/01457 (1994-01-01), None
patent: WO 98/34631 (1998-08-01), None
patent: WO 98/51705 (1998-11-01), None
patent: WO 00/47620 (2000-08-01), None
patent: WO 02/44197 (2002-06-01), None
Josephson K. et al., “Noncompetitive Antibody Neutralization of IL-10 Revealed by Protein Engineering and X-Ray Crystallography”, Structure, (Jul. 2002), vol. 10, No. 7, pp. 981-987.
Zagury D. et al., “Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines”, Proceedings of the National Academy of Science, (Jul. 3, 2001), vol. 98, No. 14, pp. 8024-8029.
Cha S. et al., “Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity”, Journal of Biological Chemistry, (Oct. 6, 2000), vol. 275, No. 40, pp. 31171-31177.
Bravo J., et al., “Receptor recognition by gp130 cytokines”, European Molecular Biology Organization, (Jun. 1, 2000), vol. 19, No. 11, p. 2403, 2406, and 2408.
Fairbrother W.J. et al., “Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site”, Biochemistry American Chemical Society, (Dec. 22, 1998), pp. 17754-17764.
Chaiken I. M., et al., “Identifying structure-function relationships in four-helix bundle cytokines: towardsde novomimetics design”, Trends in Biotechnology, (Oct. 1996), vol. 14, No. 10, pp. 369-375.
Browdy and Neimark PLLC
Mertz Prema M
Vaxconsulting
LandOfFree
Peptides for active anti-cytokine immunization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for active anti-cytokine immunization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for active anti-cytokine immunization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2769460